Skip to content

Evaluation of a prospective, multicenter, randomized, non-inferior clinical trial of the Jrecan flow reconstruction device for endovascular treatment of acute ischemic stroke

Evaluation of a prospective, multicenter, randomized, non-inferior clinical trial of the Jrecan flow reconstruction device for endovascular treatment of acute ischemic stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TOC-17013822
Enrollment
Unknown
Registered
2017-12-11
Start date
2017-12-21
Completion date
Unknown
Last updated
2017-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

Test Group:use Jrecan blood flow reconstruction device to embolectomy
Control group:use Solitaire FR to embolectomy

Sponsors

PLA Rocket Force General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18-80 years old; 2) AIS: NIHSS=6 within 8 hours; 3) mRS before onset=2; 4) angiography confirmed intracranial internal carotid artery, middle cerebral artery (MCA) trunk acute obstruction in patients; 5) The subject (or his guardian) agreed to participate in the study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1) CT or MR shows evidence of intracranial hemorrhage, or is known to have bleeding tendency; 2) CT showed low-density lesions more than 1/3 of the middle cerebral artery area, or ASPECTS 185 mmHg or DBP> 110 mmHg for patients; 8) have heart, lung, liver and kidney failure or other serious diseases (such as brain tumors, cerebral arteriovenous malformations, systemic infections, active disseminated intravascular coagulation, myocardial infarction within 12 months before enrollment , A serious history of mental illness); 9) blood glucose 3; 12) can not cooperate and tolerate interventional surgery; 13) Pregnant or lactating women; 14) is known to be severely allergic to contrast media; 15) are participating in other drug or device research; 16) Life expectancy is less than 90 days;

Design outcomes

Primary

MeasureTime frame
Revascularization rate;

Secondary

MeasureTime frame
mRS;National Institute of Health stroke scale(NIHSS);Product performance;

Countries

China

Contacts

Public ContactWeijian Jiang

PLA Rocket Force General Hospital

cjr.jiangweijian@vip.163.com+86 13901122837

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026